Skip to main content
The Egyptian Journal of Bronchology

Table 2 Comorbidities among group A patients who did not developed post-vaccine COVID-19 infection (n = 299) versus group B vaccinated participants who developed post-vaccine COVID-19 infection (n = 70)

From: Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt

 

COVID-19 vaccinated cases (n = 369)

P value*

Group A (n = 299)

Group B (n = 70)

Hypertension

7 (2.3%)

11 (15.7%)

 < 0.001

Diabetes mellitus

7 (2.3%)

6 (8.6%)

0.02

Cardiac diseases

0

3 (4.3%)

 < 0.001

Renal diseases

1 (0.3%)

1 (1.4%)

0.34

Chest diseases

2 (0.7%)

2 (2.9%)

0.16

Othersa

2 (0.7%)

2 (2.9%)

0.16

  1. Data expressed as frequency (percentage). Only significant values should be in boldface (P value was considered significant if < 0.05). COVID-19 coronavirus disease-19
  2. *All data were compared by Chi2 test
  3. aOthers include hyperthyroidism, cardiovascular diseases, gout, peptic ulcer, osteoarthritis, and typhoid fever
Back to article page